[ad_1] Galapagos has found a buyer for its once-promising JAK inhibitor Jyseleca (filgotinib), signing a letter of intent to transfer the drug and related operations to Alfasigma of Italy. Under the deal, Galapagos…
Tag: filgotinib
Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
[ad_1] Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to…